A Novel Co-Crystal of Bexarotene and Ligustrazine Improves Pharmacokinetics and Tissue Distribution of Bexarotene in SD Rats

A Novel Co-Crystal of Bexarotene and Ligustrazine Improves Pharmacokinetics and Tissue Distribution of Bexarotene in SD Rats

Bexarotene (BEX), a specific retinoic acid X receptor (RXR) agonist granted by Food and Drug Administration (FDA) approval for the clinical treatment of T cell lymphoma, has now been found to exert pharmacological effects in the nervous system, with low bioavailability and poor cerebral distribution...

Full description

Bibliographic Details
Main Authors: Shuyue Ren, Lingtai Jiao, Shiying Yang, Li Zhang, Junke Song, Haoying Yu, Jingrong Wang, Tingting Lv, Lan Sun, Yang Lu, Guanhua Du
Format: Article
Language:English
Published: MDPI AG 2020-09-01
Series:Pharmaceutics
Subjects:
pharmaceutical co-crystals
active pharmaceutical ingredients
bexarotene
solubility
bioavailability
cerebral distribution
Online Access:https://www.mdpi.com/1999-4923/12/10/906

Similar Items

Similar Items